Álvaro H Borges1. 1. Centre for Health and Infectious Diseases Research, Department of Infectious Diseases, Section 2100, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Abstract
PURPOSE OF REVIEW: To review the newest research about the effects of combination antiretroviral therapy (cART) on cancer risk. RECENT FINDINGS: HIV+ persons are at increased risk of cancer. As this risk is higher for malignancies driven by viral and bacterial coinfections, classifying malignancies into infection-related and infection-unrelated has been an emerging trend. Cohorts have detected major reductions in the incidence of Kaposi sarcoma and non-Hodgkin lymphoma (NHL) following cART initiation among immunosuppressed HIV+ persons. However, recent randomized data indicate that cART reduces risk of Kaposi sarcoma and NHL also during early HIV infection before overt immunosuppression occurs. Long-term effects of cART exposure on cancer risk are not well defined; according to basic and epidemiological research, there might be specific associations of each cART class with distinct patterns of cancer risk. SUMMARY: The relationship between cART exposure and cancer risk is complex and nuanced. It is an intriguing fact that, whether initiated during severe immunosuppression or not, cART reduces risk of Kaposi sarcoma and NHL. Further research should identify mediators of the benefit of immediate cART initiation in reducing cancer risk, understand the relationship between long-term cART exposure and cancer incidence and assess whether adjuvant anti-inflammatory therapies can reduce cancer risk during treated HIV infection.
PURPOSE OF REVIEW: To review the newest research about the effects of combination antiretroviral therapy (cART) on cancer risk. RECENT FINDINGS: HIV+ persons are at increased risk of cancer. As this risk is higher for malignancies driven by viral and bacterial coinfections, classifying malignancies into infection-related and infection-unrelated has been an emerging trend. Cohorts have detected major reductions in the incidence of Kaposi sarcoma and non-Hodgkin lymphoma (NHL) following cART initiation among immunosuppressed HIV+ persons. However, recent randomized data indicate that cART reduces risk of Kaposi sarcoma and NHL also during early HIV infection before overt immunosuppression occurs. Long-term effects of cART exposure on cancer risk are not well defined; according to basic and epidemiological research, there might be specific associations of each cART class with distinct patterns of cancer risk. SUMMARY: The relationship between cART exposure and cancer risk is complex and nuanced. It is an intriguing fact that, whether initiated during severe immunosuppression or not, cART reduces risk of Kaposi sarcoma and NHL. Further research should identify mediators of the benefit of immediate cART initiation in reducing cancer risk, understand the relationship between long-term cART exposure and cancer incidence and assess whether adjuvant anti-inflammatory therapies can reduce cancer risk during treated HIV infection.
Authors: Álvaro H Borges; Jemma L O'Connor; Andrew N Phillips; Frederikke F Rönsholt; Sarah Pett; Michael J Vjecha; Martyn A French; Jens D Lundgren Journal: J Infect Dis Date: 2015-02-26 Impact factor: 5.226
Authors: Supriya Krishnan; Jeffrey T Schouten; Denise L Jacobson; Constance A Benson; Ann C Collier; Susan L Koletar; Jorge Santana; Fred R Sattler; Ronald Mitsuyasu Journal: Oncology Date: 2011-05-23 Impact factor: 2.935
Authors: Chad J Achenbach; Ashley L Buchanan; Stephen R Cole; Lifang Hou; Michael J Mugavero; Heidi M Crane; Richard D Moore; Richard H Haubrich; Satish Gopal; Joseph J Eron; Peter W Hunt; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata Journal: Clin Infect Dis Date: 2014-02-12 Impact factor: 9.079
Authors: O A Olivero; L M Anderson; B A Diwan; D C Haines; S W Harbaugh; T J Moskal; A B Jones; J M Rice; C W Riggs; D Logsdon; S H Yuspa; M C Poirier Journal: J Natl Cancer Inst Date: 1997-11-05 Impact factor: 13.506
Authors: Chun Chao; Wendy A Leyden; Lanfang Xu; Michael A Horberg; Daniel Klein; William J Towner; Charles P Quesenberry; Donald I Abrams; Michael J Silverberg Journal: AIDS Date: 2012-11-13 Impact factor: 4.177
Authors: Antonella d'Arminio Monforte; Donald Abrams; Christian Pradier; Rainer Weber; Peter Reiss; Fabrice Bonnet; Ole Kirk; Matthew Law; Stephane De Wit; Nina Friis-Møller; Andrew N Phillips; Caroline A Sabin; Jens D Lundgren Journal: AIDS Date: 2008-10-18 Impact factor: 4.632
Authors: Álvaro H Borges; Jacqueline Neuhaus; Shweta Sharma; James D Neaton; Keith Henry; Olga Anagnostou; Teresa Staub; Sean Emery; Jens D Lundgren Journal: J Infect Dis Date: 2019-01-07 Impact factor: 5.226
Authors: Oresto Michael Munishi; Valerie McCormack; Bariki Mchome; Glory Mangi; Leah L Zullig; John Bartlett; Oscar Mapunda; Pilli Nyindo; Theresia Namwai; Charles Muiruri; Frank Kimaro; Francis Karia; Blandina T Mmbaga Journal: J Cancer Educ Date: 2020-08 Impact factor: 2.037
Authors: Benjamin R Murray; Allison Kratka; Karen A Scherr; Nir Eyal; Jennifer Blumenthal-Barby; Kenneth A Freedberg; Daniel R Kuritzkes; James K Hammitt; Regina Edifor; Madelaine N Katz; Kathryn I Pollak; Brian J Zikmund-Fisher; Scott D Halpern; Mary C Barks; Peter A Ubel Journal: J Virus Erad Date: 2019-04-01
Authors: Adam Trickey; Margaret T May; M John Gill; Sophie Grabar; Janne Vehreschild; Ferdinand W N M Wit; Fabrice Bonnet; Matthias Cavassini; Sophie Abgrall; Juan Berenguer; Christoph Wyen; Peter Reiss; Katharina Grabmeier-Pfistershammer; Jodie L Guest; Leah Shepherd; Ramon Teira; Antonella d'Arminio Monforte; Julia Del Amo; Amy Justice; Dominique Costagliola; Jonathan A C Sterne Journal: Int J Cancer Date: 2020-03-12 Impact factor: 7.396